RNA binding motif protein 23Genealiases: CAPERbeta · PP239 · RNPC4
Q-omics provides the consensus-scored RBM23 profile across patient tissues and cancer cell-line models. RBM23 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM23 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, RBM23 RNA expression shows 20,060 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where RBM23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM23 survival associations across molecular data types. RBM23 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM23 RNA expression–survival associations across cancer types. High RBM23 expression shows unfavorable associations in ACC, COAD and STAD, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM23 RNA expression.
This table summarizes RBM23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM23 shows lower tumor expression in THCA, KIRC and LUAD and higher tumor expression in LIHC, STAD and HNSC. The THCA box plot shows higher RBM23 RNA expression in normal versus tumor tissue (log2 FC = −0.834, t-test p < 0.001).
This table shows molecular features associated with RBM23 in patient tissues and cancer cell lines. In patient samples, RBM23 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
